Provided by Tiger Trade Technology Pte. Ltd.

VYNE Therapeutics Inc.

0.3700
-0.0042-1.12%
Post-market: 0.3656-0.0044-1.19%19:38 EST
Volume:379.05K
Turnover:144.36K
Market Cap:12.32M
PE:-0.47
High:0.3892
Open:0.3830
Low:0.3656
Close:0.3742
52wk High:4.30
52wk Low:0.2805
Shares:33.29M
Float Shares:30.82M
Volume Ratio:0.76
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7884
EPS(LYR):-0.9353
ROE:-70.67%
ROA:-41.51%
PB:0.38
PE(LYR):-0.40

Loading ...

Company Profile

Company Name:
VYNE Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
13
Office Location:
685 Route 202/206 N,Suite 301,Bridgewater,New Jersey,United States
Zip Code:
08807
Fax:
- -
Introduction:
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Directors

Name
Position
David Domzalski
President,Chief Executive Officer and Director
Patrick LePore
Director and Lead Independent Director
Elisabeth Sandoval Little
Director
Sharon Barbari
Director
Steven Basta
Director

Shareholders

Name
Position
David Domzalski
President,Chief Executive Officer and Director
Tyler Zeronda
Chief Financial Officer and Treasurer
Iain Stuart
Chief Scientific Officer
Mutya Harsch
Chief Legal Officer, General Counsel and Secretary